Published in Front Oncol on December 09, 2014
Ponatinib for Squamous Cell Lung and Head and Neck Cancers | NCT01761747
Treatment of advanced squamous cell carcinoma of the lung: a review. Transl Lung Cancer Res (2015) 0.84
The treatment of metastatic non-small cell lung cancer in a new era of personalized medicine. Front Oncol (2015) 0.75
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 52.99
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med (2012) 35.24
Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med (2005) 31.48
International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thorac Oncol (2011) 21.49
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol (2008) 17.30
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet (2008) 10.74
Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol (2004) 7.87
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet (2009) 7.50
Cancer immunotherapy comes of age. J Clin Oncol (2011) 5.87
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. Lancet Oncol (2011) 5.06
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
Docetaxel plus nintedanib versus docetaxel plus placebo in patients with previously treated non-small-cell lung cancer (LUME-Lung 1): a phase 3, double-blind, randomised controlled trial. Lancet Oncol (2014) 4.02
Role of KRAS and EGFR as biomarkers of response to erlotinib in National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol (2008) 3.97
The differential efficacy of pemetrexed according to NSCLC histology: a review of two Phase III studies. Oncologist (2009) 3.92
Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer (2006) 2.27
Overall survival improvement in patients with lung cancer and bone metastases treated with denosumab versus zoledronic acid: subgroup analysis from a randomized phase 3 study. J Thorac Oncol (2012) 2.15
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer (2006) 2.14
How sensitive are epidermal growth factor receptor-tyrosine kinase inhibitors for squamous cell carcinoma of the lung harboring EGFR gene-sensitive mutations? J Thorac Oncol (2013) 2.11
Lung carcinogenesis by tobacco smoke. Int J Cancer (2012) 2.06
Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap). Ann Oncol (2013) 2.04
Zoledronic acid and survival in patients with metastatic bone disease from lung cancer and elevated markers of osteoclast activity. J Thorac Oncol (2008) 1.98
Disrupting proton dynamics and energy metabolism for cancer therapy. Nat Rev Cancer (2013) 1.93
Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors. Support Care Cancer (2013) 1.74
Nucleotide-based therapies targeting clusterin chemosensitize human lung adenocarcinoma cells both in vitro and in vivo. Mol Cancer Ther (2004) 1.63
Cigarette smoking prevalence in US counties: 1996-2012. Popul Health Metr (2014) 1.53
Expression of TTF-1 and cytokeratins in primary and secondary epithelial lung tumours: correlation with histological type and grade. Histopathology (2004) 1.45
FGFR1 amplification in squamous cell carcinoma of the lung. J Thorac Oncol (2012) 1.43
Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control (2013) 1.42
A novel five-antibody immunohistochemical test for subclassification of lung carcinoma. Mod Pathol (2009) 1.35
Systematic review with meta-analysis of the epidemiological evidence in the 1900s relating smoking to lung cancer. BMC Cancer (2012) 1.33
High expression of folate receptor alpha in lung cancer correlates with adenocarcinoma histology and EGFR [corrected] mutation. J Thorac Oncol (2012) 1.28
Genetic changes in squamous cell lung cancer: a review. J Thorac Oncol (2012) 1.23
Large-scale comparative analyses of immunomarkers for diagnostic subtyping of non-small-cell lung cancer biopsies. Histopathology (2012) 1.16
Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications. Clin Lung Cancer (2004) 1.11
ALK/EML4 fusion gene may be found in pure squamous carcinoma of the lung. J Thorac Oncol (2014) 1.11
Analysis of major known driver mutations and prognosis in resected adenosquamous lung carcinomas. J Thorac Oncol (2014) 1.08
Subtyping of non-small cell lung carcinoma: a comparison of small biopsy and cytology specimens. J Thorac Oncol (2011) 1.07
High-risk human papillomavirus-positive lung cancer: molecular evidence for a pattern of pulmonary metastasis. J Thorac Oncol (2013) 1.06
Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis. Cancer Chemother Pharmacol (2013) 1.04
Randomised, double-blind trial of carboplatin and paclitaxel with daily oral cediranib or placebo in patients with advanced non-small cell lung cancer: NCIC Clinical Trials Group study BR29. Eur J Cancer (2013) 1.03
Relationship between EGFR expression, EGFR mutation status, and the efficacy of chemotherapy plus cetuximab in FLEX study patients with advanced non-small-cell lung cancer. J Thorac Oncol (2014) 0.99
Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint inhibitors. Am J Clin Oncol (2015) 0.96
Beyond Breast and Ovarian Cancers: PARP Inhibitors for BRCA Mutation-Associated and BRCA-Like Solid Tumors. Front Oncol (2014) 0.94
Safety and efficacy analysis by histology of weekly nab-paclitaxel in combination with carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer. Ann Oncol (2013) 0.92
Efficacy of epidermal growth factor receptor-tyrosine kinase inhibitors for Chinese patients with squamous cell carcinoma of lung harboring EGFR mutation. J Thorac Dis (2013) 0.90
Downfall of iniparib: a PARP inhibitor that doesn't inhibit PARP after all. J Natl Cancer Inst (2014) 0.88
The clinical relevance of KRAS gene mutation in non-small-cell lung cancer. Curr Opin Oncol (2014) 0.86
The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent non-small-cell lung cancer: a Canadian national consensus statement. Curr Oncol (2009) 0.86
Targeting angiogenesis in squamous non-small cell lung cancer. Drugs (2014) 0.83
Profile of pazopanib and its potential in the treatment of epithelial ovarian cancer. Int J Womens Health (2014) 0.82
Lung cancer histologies associated with emphysema on computed tomography. Lung Cancer (2011) 0.80
nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer. Expert Rev Anticancer Ther (2014) 0.80
Unmet needs in squamous cell carcinoma of the lung: potential role for immunotherapy. Med Oncol (2014) 0.80
Stage III non-small-cell lung cancer: population-based patterns of treatment in British Columbia, Canada. J Thorac Oncol (2012) 0.79
Does histology predict survival of advanced non-small cell lung cancer patients treated with platin-based chemotherapy? An analysis of the Eastern Cooperative Oncology Group Study E1594. Lung Cancer (2013) 0.78
Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors. Cancer Med (2014) 0.78
PARP inhibitors: an interesting pathway also for non-small cell lung cancer? Curr Pharm Des (2014) 0.78
Analysis of a novel protocol of combined induction chemotherapy and concurrent chemoradiation in unresected non-small-cell lung cancer: a ten-year experience with vinblastine, Cisplatin, and radiation therapy. Clin Lung Cancer (2010) 0.77
Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study. J Thorac Oncol (2014) 0.76
[Relationship of clusterin expression with Bax and p53 expression in non-small cell lung cancer]. Zhongguo Fei Ai Za Zhi (2007) 0.76